Amgen’s (AMGN) Neutral Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Amgen (NASDAQ:AMGN) in a research report sent to investors on Monday morning,Benzinga reports. They currently have a $350.00 price target on the medical research company’s stock.

Other analysts also recently issued research reports about the stock. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Freedom Capital upgraded Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Finally, Canaccord Genuity Group initiated coverage on Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $356.00.

Amgen Stock Up 1.9%

Shares of NASDAQ:AMGN opened at $373.30 on Monday. The business has a 50-day moving average price of $342.43 and a 200 day moving average price of $348.09. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The company has a market capitalization of $201.47 billion, a price-to-earnings ratio of 25.96, a PEG ratio of 3.68 and a beta of 0.41. Amgen has a 12-month low of $269.77 and a 12-month high of $391.29.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same quarter last year, the firm posted $4.90 earnings per share. Amgen’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Sell-side analysts expect that Amgen will post 22.39 EPS for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amgen

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. raised its stake in Amgen by 10.0% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock worth $157,584,000 after purchasing an additional 43,884 shares during the period. Curtis Advisory Group LLC purchased a new stake in Amgen during the fourth quarter worth approximately $1,669,000. Adell Harriman & Carpenter Inc. increased its position in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after acquiring an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new position in shares of Amgen in the 4th quarter valued at $22,441,000. Finally, Robinhood Asset Management LLC purchased a new stake in Amgen during the 4th quarter worth $17,526,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Zacks upgraded Amgen to a Buy (Rank #2), signaling improving earnings outlook and potentially supporting the stock in the near term. Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
• Positive Sentiment: Truist raised its price target on Amgen from $327 to $340, indicating somewhat better valuation expectations, even while keeping a Hold rating. Benzinga report on Truist price target increase
• Neutral Sentiment: Cantor Fitzgerald reiterated a Neutral rating with a $350 target, suggesting the stock is viewed as fairly valued relative to recent levels. Benzinga report on Cantor Fitzgerald rating
• Neutral Sentiment: Amgen’s stock also drew attention from market commentary noting it had been slipping while the broader market advanced, reflecting relative underperformance rather than a company-specific catalyst. Amgen (AMGN) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Investor sentiment remains weighed down by Tavneos scrutiny, including FDA efforts to challenge the drug’s approval and the retraction of a key supporting study, which could cloud Amgen’s sales outlook and pipeline confidence. Amgen Slides as Tavneos Scrutiny and Pipeline Questions Weigh on Shares

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.